Northwest Biotherapeutics brain cancer clinical data shows increased patient survival

By Elaine Rigoli

Tampa, Fla., Aug. 28 - Northwest Biotherapeutics updated its phase 1 survival and progression data on patients from two clinical trials who have received DCVax-Brain, a therapeutic personalized cancer vaccine, which showed that:

• Seven of 16 patients are still alive, with follow-up times ranging from 18 to 75 months;

• Six of these seven patients have shown no cancer recurrence;

• In a landmark analysis at 24 months, 63% of treated patients were alive, while in historical controls 26% of patients were alive;

• 14 of 16 patients surpassed the historical control median survival of 15 months.

The company said patients from these phase 1 trials will continue to receive booster injections of DCVax-Brain over the next year.

Based in Bothell, Wash., Northwest is a biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.